Harvard Bioscience, Inc.
Price Action
Technical Summary
EMERGING TRENDHarvard Bioscience, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 57), indicating performance broadly in line with the market. Earnings growth of 93% provides fundamental context to the price action. Investors should exercise caution due to high volatility (132% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.12 | +8.35% | ABOVE |
| 50 SMA | $6.12 | +8.31% | ABOVE |
| 100 SMA | $5.81 | +14.14% | ABOVE |
| 150 SMA | $6.04 | +9.81% | ABOVE |
| 200 SMA | $5.79 | +14.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is HBIO in an uptrend right now?
HBIO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is HBIO overbought or oversold?
HBIO's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is HBIO outperforming the market?
HBIO has a Relative Strength (RS) Rating of 57 out of 99. HBIO is performing about average compared to the market.
Where is HBIO in its 52-week range?
HBIO is trading at $6.63, which is 71% of its 52-week high ($9.40) and 69% above its 52-week low ($0.59).
How volatile is HBIO?
HBIO has a Beta of 1.71 and 52-week volatility of 132%. It's more volatile than the S&P 500 - expect bigger swings.